Expectancy effects

Expectancy effects describe how a person’s expectations can help shape a psychedelic experience and the meaning later assigned to it. In this account, they are not a peripheral nuisance but a central difficulty for psychedelic science: what people are told, the theories held by their therapists, and the conditions of a session may all influence what the drug experience becomes. That influence complicates claims about cause and cure, yet does not by itself establish that a treatment has no value.

How expectations shape experience

Psychedelic experiences are especially open to suggestion. Someone told to expect spiritual revelation may experience one; a person warned of temporary madness may interpret the experience in those terms. Suggestions about the collective unconscious, cosmic consciousness, or revisiting birth trauma can likewise furnish a frame through which an experience is understood. Expectations do not merely color a report after the fact in this account: they can help organize the experience as it unfolds.

The influence can extend beyond an individual session. After Aldous Huxley published The Doors of Perception in 1954, his account of mescaline and his Eastern-influenced mysticism helped shape the language through which later psychedelic experiences were imagined. That influence could reach people who had never read the book: the Eastern coloring became associated with LSD, and the Beatles’ Tomorrow Never Knows carried that sensibility into popular culture. Timothy Leary and his Harvard colleagues amplified the current by writing a bestselling manual for psychedelic experience based on the Tibetan Book of the Dead.

The cultural influence ran in both directions. A scientist gave mescaline to Huxley hoping that a great writer’s descriptions and metaphors would help researchers make sense of an experience they struggled to interpret. Huxley’s writing then helped supply language and expectations for later experiences. The result is an epistemological feedback loop: researchers seek descriptions of an elusive phenomenon, those descriptions shape what future participants expect, and the resulting experiences can seem to confirm the account that helped produce them. The question is not simply whether Huxley described the modern psychedelic experience, but whether his description partly helped create it.

A problem for science and therapy

This feedback loop makes the standard tools of clinical research difficult to apply. If expectation strongly affects what participants experience, researchers must ask how to blind patients and clinicians, control expectations, or isolate the effect of a drug from the influence of a therapist and the surroundings. Set and setting matter to the experience, yet controlling them may remove some of the conditions that support a successful session. A rigorously controlled study can therefore be less like the therapy it aims to evaluate.

Sidney Cohen sharpened the problem by observing that patients’ reported insights often reflected their therapists’ theories. Patients working with Freudian therapists returned with accounts framed around childhood trauma, sexual drives, and oedipal emotions; those with Jungian therapists reported archetypes associated with the collective unconscious; and patients treated by Rankians described recovered birth traumas. The pattern suggested that psychedelic suggestibility could make a therapist’s favored explanation appear confirmed by the patient.

Cohen nevertheless distinguished a scientific dilemma from a therapeutic one. If therapist and patient both firmly believed an explanation, he considered that it might still function as insight or be useful as insight. He recognized that this position approached shamanism and faith healing, and regarded its scientific implications as troubling. The same tension appears in the idea of psychedelics as an active placebo: the drug has effects, but some of what follows may be generated by the person and the treatment context. Stanislav Grof’s description of psychedelics as nonspecific amplifiers of mental processes offers a related formulation. Neither idea resolves how much benefit belongs to the molecule, the expectations it awakens, or the therapeutic relationship.

Treatment conditions and conflicting results

The Saskatchewan alcohol-treatment research illustrates how strongly context could matter. At Weyburn hospital, Humphry Osmond and Abram Hoffer heard from volunteers that the environment affected the kind of LSD experience they had. They came to value an engaged, empathetic therapist, ideally one who had experienced LSD. They also suspected that some psychotic reactions might be artifacts of the white room and white-coated clinician, rather than straightforward evidence of what the drug did under all conditions. Their work thus raised the possibility that an apparently neutral clinical setting was not neutral in its effects.

By the end of the 1950s, LSD was widely regarded in North America as a remarkable treatment for alcohol addiction, and the Saskatchewan provincial government helped make LSD therapy a standard treatment option in the province. The Addiction Research Foundation in Toronto later attempted to replicate the results with stricter controls. Clinicians put volunteers in neutral rooms, avoided engaging with them except to administer extensive questionnaires, and at times constrained or blindfolded them. The results did not match those reported by Osmond and Hoffer, and some volunteers had frightening experiences. Critics took the outcome as evidence that the treatment did not work as well under rigorous controls; supporters saw evidence that attention to set and setting was essential. Both readings capture part of the difficulty: changing the conditions changes what is being tested.

The Concord Prison Experiment provides a further caution about claims of efficacy, though its reported outcome cannot be attributed to expectancy effects alone. Timothy Leary reported that ten months after release, 25 percent of the psilocybin recipients had returned to jail, compared with 80 percent of a control group. Decades later, Rick Doblin’s reconstruction for the Multidisciplinary Association for Psychedelic Studies found no statistically significant difference in recidivism between the groups, and the study’s methodological shortcomings had already drawn criticism from David McClelland. The reversal underscores why striking outcomes require scrutiny of study design and analysis rather than acceptance as proof.

Promise, evidence, and uncertainty

Later studies renewed the debate without eliminating it. In the 2016 New York University and Johns Hopkins University cancer trials, about 80 percent of participants showed clinically significant reductions in anxiety and depression, with effects lasting at least six months. The intensity of reported mystical experience closely correlated with symptom improvement. That association is notable, but correlation does not determine whether mystical experience caused improvement, whether expectations shaped both reports, or whether other features of treatment contributed.

The depression feasibility study directed by Robin Carhart-Harris in David Nutt’s lab at Imperial College London was also promising but preliminary. It began with twelve people with treatment-resistant depression, all of whom knew they were receiving psilocybin and none of whom had a control group. Symptoms improved in all participants after a week, and two-thirds were depression-free; at three months, seven still showed substantial benefit. After the study expanded to twenty participants, six remained in remission at six months, while others had relapsed to varying degrees. The findings suggested rapid benefit and good tolerability in this small group, not a definitive estimate of efficacy.

The account therefore treats expectancy effects as both a methodological warning and a reason for interpretive caution. Early studies can be affected by small samples, the selection of likely responders, unusually attentive therapists, and strong placebo effects. Initial success should be understood as a promising signal rather than proof that psychedelic therapies cure a range of disorders. At the same time, the possibility that expectation participates in a therapeutic experience does not make the experience unreal or necessarily useless. The unresolved challenge is to distinguish, as far as research can, what the drug contributes from what belief, setting, and care make possible.